Andersen Group Inc.

**Signal Note: Driehaus Capital Initiates $17.9M ANDG Position** Driehaus's entry into Andersen Group signals confidence in the company's pipeline, likely driven by near-term clinical or regulatory catalysts; however, the lack of public detail on ANDG's lead program warrants clarification on whether this reflects confidence in their core assets or a turnaround thesis. Given Driehaus's growth-focused mandate and material allocation size (~$17.9M position), this suggests the firm sees asymmetric risk-reward, though investors should verify clinical trial timelines and competitive positioning before drawing conclusions on conviction level.